95% of Advanced Prostate Cancer Consensus Conference Panellists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panellists) and FDA approve this as control arm for trials?? “Unethical” says ONCODOC from the floor, as did Vinay Prasad MD MPH on GU Cast GU Cast | Urology podcast! #APCCC24

Energizing morning at ClevelandZooSociety in support of PanCAN!

Daniel E Spratt 💯 agree. The therapeutic agent is ionising radiation. It's insane that regulators anywhere would allow Lu177 administration to be supervised by non radiation specialists. No fundamental radiobiology knowledge = clinical risk. #radoncdomain

Pierre Blanchard, MD Daniel E Spratt Thomas Hope Louise Emmett Ken Herrmann Advanced Prostate Cancer Consensus Conference Declan Murphy tombal As Dan said, please can we make a point of distinguishing between administered activity and absorbed dose

Chris Parker Pierre Blanchard, MD Daniel E Spratt Thomas Hope Louise Emmett Advanced Prostate Cancer Consensus Conference Declan Murphy tombal We need tons differentiate between injected activity, absorbed normal organ dose and absorbed tumor dose.

Amazing turnout to Cleveland’s #PurpleStride2024 ! Proud to have our very own Lauren Henke, MD, MSCI kicking off the event with PanCAN and Natalie Herbick from fox8news 💜
We are honored to share these moments, steps, and mission with our patients 💜

Brilliant lecture by Michael Hofman on differences between PSMA tracers for diagnostics and therapy in #prostatecancer
1. PSMA11, DCFPyL or PSMA7 likely interchangeable
2. For therapy PSMA617 and I&T: likely radio equivalent
#APCCC24

HERE IN #APCCC24 🇨🇭
IT'S ALL ABOUT THAT PSMA

Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin Neeraj Agarwal, MD, FASCO Ravindran Kanesvaran Simon C
Eleni Efstathiou Dra. María Natalia Gandur Quiroga A/Prof. Shahneen Sandhu
Christopher Sweeney, MBBS Daniel E Spratt Howard Soule
neal shore Robert Reiter Dana Rathkopf
Colin Pritchard…

To be fair, some of us treat the whole pelvis in 5 fractions in this setting which is technically SBRT 😁. Himanshu Nagar

In patients who receive salvage radiation therapy for BCR, who needs additional systemic therapy, What and for how long? Presentation by Daniel E Spratt Case Comp Cancer Ctr. #APCCC24 written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3vXJE4c Advanced Prostate Cancer Consensus Conference

Enjoying controversial topics in sunny Lugano! Just a few cowbells but lots of impactful discussion! silke gillessen Advanced Prostate Cancer Consensus Conference DCI Center for Prostate & Urologic Cancers

Excellent talk by ⁦Daniel E Spratt⁩ at #APCCC24 on genomic and MMAI classifiers in M0 #prostatecancer .

Issues remain about access, dichotomization and added value compared to currently used risk markers (% positive cores, length of Pattern 4, MRI T stage, PSA density…)

Very interesting presentation on the duration of ADT based on 22-genes Genomic Classifier by Daniel E Spratt Advanced Prostate Cancer Consensus Conference @APCCC2024

#APCCC24 Advanced Prostate Cancer Consensus Conference outstanding talk by Daniel E Spratt on personalization of Rx in localized #ProstateCancer 👉Role of AI based biomarkers and genomic classifiers for de-
and escalation of Rx 👇 OncoAlert UroToday.com silke gillessen Neha Vapiwala aurelius omlin

How can a genomic classifier transform the management of prostate cancer? Presenting compelling evidence, Daniel E Spratt demonstrates the significant role that genomic classification plays role in both prognostication and defining role of kong ter hormonal treatment.
#Apccc24 …

Using Decipher and artificial intelligence biomarkers to personalize the use and duration of androgen deprivation therapy for high-risk #Prostatecancer -Daniel E Spratt #apccc24